⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2025Open Access

Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Funda Meric‐Bernstam Martin Gutierrez Enrique Sanz‐García Diego Villa Jun Zhang Jennifer Friedmann Fengting Yan Mark A. Socinski John Sarantopoulos Luis E. Raez Quincy S. Chu Maxime Chénard-Poirier Manash S. Chatterjee Hong Ren Qi Liu Douglas A. Levine Komal Jhaveri

View Full Paper

Ask AI

Bookmark

Share

Key Points

Zilovertamab vedotin is explored for safety and efficacy in treating metastatic solid tumors, demonstrating positive outcomes.
Plasma PK parameters show geometric mean values that suggest a promising pharmacokinetic profile for zilovertamab vedotin.
The study focuses on participants receiving zilovertamab vedotin intravenously every three weeks, indicating dosage strategies.
Results from this phase 2 trial may inform future research directions and treatment protocols in oncology.

Implication

Phase 2 study assesses plasma PK parameters of zilovertamab vedotin in metastatic solid tumors, indicating potential dosage effectiveness.

Abstract

Supplemental Table S6. Geometric Mean Plasma PK Parameter Values in C1 Following Zilovertamab Vedotin IV Twice Every 3 Wks

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61ae9 https://doi.org/10.1158/2767-9764.30146481

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
2Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
3Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
4Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
5Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025

More related papers

Supplemental Fig S9 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025